Tıp Fakültesi / Faculty of Medicine

Permanent URI for this collectionhttps://hdl.handle.net/11727/1403

Browse

Filters

2016 - 20203

Settings

search.filters.applied.f.language: search.filters.language.engSubject: search.filters.subject.immunosuppression

Search Results

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Reactivation of Resolved Hepatitis B Virus Infection Before The Relapse of Lymphoma : Immunosuppressive Effect of the Lymphoproliferative Disorders ?
    (2016) Gokturk, Huseyin Savas; Unler, Gulhan Kanat; Gokturk, Bahar; https://orcid.org/0000-0003-0182-002X; 26852769
    Hepatitis B virus (HBV) infection is a heterogeneous disease with distinct phases determined mainly by the interaction between virus replication and host immune response. HBV reactivation can occur spontaneously, developing resistance to antiviral treatment while the patient is undergoing treatment, after cessation of antiviral drugs, or be triggered by immunosuppressive drugs and chemotherapy. HBV reactivation can be severe and sometimes fatal because of liver failure. Here we report a patient with resolved HBV infection who presented with reactivation before being diagnosed with a relapse of non-Hodgkin lymphoma.
  • No Thumbnail Available
    Item
    Editorial: Cutaneous B-Cell Lymphomas
    (2020) Alaibac, Mauro; Seckin, Deniz; Quaglino, Pietro; 33363042
  • No Thumbnail Available
    Item
    Management of Kaposi sarcoma after solid organ transplantation: A European retrospective study
    (2019) Delyon, Julie; Rabate, Clementine; Euvrard, Sylvie; Harwood, Catherine A.; Proby, Charlotte; Gulec, Tulin; Seckin, Deniz; Del Marmol, Veronique; Bouwes-Bavinck, Jan Nico; Ferrandiz-Pulido, Carla; Ocampo, Maria Andrea; Barete, Stephane; Legendre, Christophe; Frances, Camille; Porcher, Raphael; Lebbe, Celeste; 30902727
    Background: Systemic therapeutic management of post-transplant Kaposi sarcoma (KS) is mainly based on 3 axes: reduction of immunosuppression, conversion to mammalian target of rapamycin (mTOR) inhibitors, chemotherapy, or a combination of these. Objective: To obtain an overview of clinical strategies about the current treatment of KS. Methods: We conducted a multicenter retrospective cohort study including 145 solid organ transplant recipients diagnosed with KS between 1985 and 2011 to collect data regarding first-line treatment and response at 6 months. Results: Overall, 95%, 28%, and 16% of patients had reduction of immunosuppression, conversion to mTOR inhibitor, and chemotherapy, respectively. Patients treated with chemotherapy or mTOR inhibitor conversion were more likely to have visceral KS. At 6 months, 83% of patients had response, including 40% complete responses. Limitations: The retrospective design of the study. Conclusion: Currently available therapeutic options seem to be effective to control KS in most patients. Tapering down the immunosuppressive regimen remains the cornerstone of KS management.